



## FORMULATION & EVALUATION OF BUDESONIDE CONTROLLED RELEASE CAPSULES BY SUSPENSION LAYERING METHOD

Verma Mithun and Gupta Vishvnath \*

Globus College of Pharmacy, Bhojpur road, Bangrasia, Bhopal (M.P), 462 045

**Abstract:** The study was undertaken with an aim to formulate budesonide controlled release capsules. The drug budesonide is corticosteroid and used for the treatment of Crohn's disease. Before going to develop the formulation, a detail product literature review was carried out to know about the innovator's product and the patent status of the drug. Preformulation study involving drug -excipients compatibility was done initially and results indicated the compatibility with all the tested excipients. The study was carried out by solution/suspension matrix layering method.

In this method first drug and polymer solutions were mixed, coating was done on the sugar spheres; further enteric coating was done on polymer matrix coated pellets. Different trials were conducted with various percentages of polymer in first stage and second stage (during enteric coating), and the formulation was finally optimized based on the drug release profile.

Pellets were evaluated by *in vitro* dissolution. These studies revealed that the F6 pellets were found to be release the drug almost comparable to that of innovator's product. Further, the F6 formulation was subjected to release studies at different pH conditions and found to have similar release profile as that of innovator. The *in vitro* dissolution tests were performed and f2 values were calculated for all trials. Dissolution profile of formulation F6 matched with that of the innovator's product and f2 value was satisfactory. Stability studies were also performed; both accelerated and long term stability studies were conducted for two months. During this study, the formulation F6 was found to be stable and no differences in the assay and release characteristics were noticed.

**Key-Words:** Multiunit Pellet Systems, Suspension Layering Method, Budesonide, Controlled Release.

**For Correspondence:**

vermampharma@gmail.com.

Received on: February 2020

Accepted after revision: March 2020

Downloaded from: [www.johronline.com](http://www.johronline.com)

**Introduction:** Pharmaceutical oral dosage forms have been used widely for decades mainly due to their convenience of administration and their suitability for delivery of drugs for systemic effects. The most commonly used pharmaceutical dosage forms today include tablets, capsules, granules and

pellets<sup>1-4</sup>. These dosage forms are designed either for improving the physical and mechanical properties of materials during manufacture and/or for providing a desired drug delivery system. Over the past 30 years as the expense and complications involved in marketing new drugs entities have increased with concomitant recognition of therapeutic advantage of controlled drug delivery, greater attention has been focused on development of sustained or controlled drug delivery system<sup>5-9</sup>. Budesonide is a newer type of corticosteroid for treating Crohn's disease. Like other corticosteroids, budesonide is a potent anti-inflammatory medication. Unlike other corticosteroids, however, budesonide acts only *via* direct contact with the inflamed tissues and not systemically<sup>10-12</sup>. As soon as budesonide is absorbed into the body, the liver converts it into inactive chemicals. Therefore, for effective treatment of Crohn's disease, budesonide, like topical 5-ASA, must be brought into direct contact with the inflamed intestinal tissue<sup>13-17</sup>. The main objective of the work is to do develop a pharmaceutically equivalent controlled release formulation of a corticosteroid, Budesonide comparable to innovator's formulation for the treatment of Crohn's disease.

### Experimental

**Materials:** Hydroxy propyl methyl cellulose E5, Tween 80, Ethyl cellulose 7cps, Hydroxy

propyl methyl cellulose phthalate 55s, Eudragit L-100 55, Aqua coat ECD, Diethyl phthalate, Triethyl citrate, Cetyl alcohol, Talc, Povidone, Isopropyl alcohol.

### Methods: Solution/Suspension Layering By Matrix Layer Formulation

Solution/suspension layering involved only two steps,

1. Drug and polymer matrix layering
2. Enteric coating
  - i) Enteric coating of polymer coated pellets by using HPMCP-55s
  - ii) Enteric coating by using Eudragit L-100-55

**Drug and polymer matrix layering on sugar spheres:** The required quantity of sugar spheres (18/20#) were weighed and transferred into a fluidized bed processor and required quantity of triethyl citrate and polysorbate – 80 were dissolved in specified volume of water. Required volume of Aquacoat ECD (signet chem. Corp.) was added to above solution under continuous stirring. Later required quantity of budesonide was dispersed in above suspension by stirring. This suspension was sprayed on sugar spheres by bottom spray technique. This drug and polymer matrix layered pellets were used for enteric coating.

**Table 1: Composition of drug and polymer matrix coated pellets for the formulation trials (F1-F6).**

Name of the Excipients	Weight of the Excipients (gm)					
	F1	F2	F3	F4	F5	F6
Formulation Code						
Budesonide (1%)	6.0	6.0	6.0	6.0	6.0	6.0
Sugar spheres	575	575	575	575	575	575
Aquacoat ECD	12.0	12.0	10.5	10.5	9.0	9.0
Polysorbate (10% of	0.60	0.60	0.60	0.60	0.60	0.60
Tri ethyl citrate (20%	2.40	2.40	2.10	2.10	1.80	1.80
Water	q.s	q.s	q.s	q.s	q.s	q.s

**Table 2: Composition of Material Used For Matrix Layering**

Name of the excipients	Weight of the excipients(mg/gm)	FBC operation conditions
Budesonide	10	Atomizing air pressure-2lb/in <sup>2</sup> (2bar) Inlet temperature – 50°C Bed temperature – 43°C Spray RPM – 3-8 Exhaust RPM (blower) – 299
Sugar spheres	834.66	
Aquacoat ECD	23.3	
Polysorbate 80	1	
Triethyl citrate	5	
Water	q.s	

**Enteric Coating Of Polymer Coated Pellets By Using HPMCP-55s.:** The required polymer coated pellets were loaded into the FBC and required quantity of diethyl phthalate and cetyl alcohol were dissolved in specified volume of isopropyl alcohol and acetone mixture. Later,

Hydroxy propyl methyl cellulose phthalate 55s, dissolved in above solution and stirred for 20min. required quantity of talc was added to solution by stirring. The solution was sprayed on polymer coated pellets by bottom spray FBC.

**Table 3: Composition of Material Used For Enteric Coating**

Name of the excipients	Weight of the excipients (mg/gm)	FBC operation conditions
Hydroxy propyl methyl cellulose phthalate 55s	120	Atomizing air pressure-2lb/in <sup>2</sup> (2bar) Inlet temperature – 48°C Bed temperature – 43°C Spray RPM – 8-10 Exhaust RPM (blower) – 299
Diethyl phthalate	12	
Cetyl alcohol	6	
Talc	5	
Acetone: Iso propyl alcohol	q.s	

**Enteric coating by using Eudragit L-100-55**  
The required quantity of drug-polymer matrix layered pellets were loaded into the FBC and required quantity of triethyl citrate and Eudragit L-100-55 were dissolved in specified volume of

isopropyl alcohol and acetone mixture under continuous stirring for 20min. later required quantity of talc was added to above solution on drug-polymer matrix layered pellets in bottom spray FBC.

**Table 4: Formulation Ingredients For Enteric Coating And Operation Conditions**

Name of the excipients	Weight of the excipients (mg/gm)	FBC operation Conditions
Eudragit L-100 55	120	Atomizing air pressure-2lb/in <sup>2</sup> (2bar) Inlet temperature – 50°C Bed temperature – 40°C Spray RPM – 3-6 Exhaust RPM (blower) – 299
Triethyl citrate	12	
Talc	30	
Acetone: Iso propyl alcohol(3:1)	q.s	

**Results and Discussion**

**Dissolution of pellets:** Dissolution was conducted first two hours in pH 1.2 buffers and then followed by 10hrs in phosphate buffer pH 7.5.

**Assay of enteric coated pellets:**

**Assay standard preparation:** about 50mg of budesonide working standard was accurately weighed in a 100ml volumetric flask. About 50ml of acetonitrile was added and sonicated for 10min. made up to 100ml with 3.2 pH buffer. Five ml of above standard was taken into 100ml volumetric flask and made up to 100ml with pH 3.2 buffer.

**Assay test preparation:** about 1.25gm of budesonide enteric pellets were taken into 100ml volumetric flask containing 50ml acetonitrile and sonicated for 30min. made up to volume with pH 3.2 buffer and filtered through 0.45µ membrane filter.

Five ml of above solution was taken into 100ml volumetric flask and diluted with pH3.2 buffer up to 100ml.

**Stability Protocol**

**TABLE 5: STABILITY CONDITIONS APPLIED IN THE STUDY**

Storage conditions	Duration
40 <sup>0</sup> C+2 <sup>0</sup> C/75%RH+5%	1,2 Months
25 <sup>0</sup> C+2 <sup>0</sup> C/60%RH+5%	1,2 Months

The following equation was used to calculate the assay value of given sample.

$$= \frac{\text{At} \times 5 \times 100 \times 25 \times \text{P} \times 1000}{\text{As} \times 100 \times 100 \times \text{Wt} \times 5 \times 100}$$

Where,


At = Peak area of budesonide sample.

As = Peak area budesonide for working standard preparation

Wt = Weight of budesonide test sample taken for assay

P = Potency of budesonide

**Stability Studies:** In order to assess the stability of drug product, accelerated stability studies were conducted for the following development batches of budesonide CR capsules. The development batches were kept on stability in 60cc wide mouth HDPE container containing 1g silica gel canister and Pharma grade polyester cotton closed with CRC closure with HS123 printed liner.



**Figure 1: Graphical Representation of Dissolution Profiles Of Stability Studies Conducted At 25<sup>0</sup>c/60%Rh Of F6**

**Conclusion:** Compatibility studies at different temperatures and relative humidity showed that drug itself was stable at higher temperature and relative humidity, as well as compatible with all above used excipients.

From the drug release profile and histograms, it was found that Eudragit L100 55 enteric coated formulation (F1) released more drug in comparison with HPMC phthalate enteric coated formulation (F2). However, F1 and F2 were not matching in their release profile with that of innovator, failing at all time intervals. From the drug release profile and histograms, it was found that Eudragit L100 55 enteric coated formulation (F4) released more drug in comparison with HPMC phthalate enteric coated formulation (F3). Thus, the nature of the enteric polymer could also affect the release rate from dosage form.

From the drug release profile and histograms, it was observed that Eudragit L100 55 enteric coated formulation (F5) released more drug in comparison with HPMC phthalate enteric coated formulation (F6). Thus, the nature of the enteric polymer could also affect the release rate from dosage form. Drug release from F5 was not matching with that of innovator, failing at all time intervals as per innovator's profile. Drug release from F6 was matching with that of innovator at all time points, and was considered as best formulation when with other formulations. Formulation F4 was also matching with that of innovator at 3<sup>rd</sup> and 4<sup>th</sup> time points, but F6 was matching with that of innovator at all time intervals. So, formulation F6 was found suitable for budesonide CR 3mg capsules preparation.

In Stability studies observed that both accelerated and long term stability studies were conducted for two months. During this study, the formulation F6 was found to be stable and no differences in the assay and release characteristics were noticed.

**Acknowledgement:** We are grateful to the management of Globus College of Pharmacy,

Bhopal for their constant support and encouragement to complete this research work.

#### References

1. Anju, G., Virendra, B., Latest Advancement in patented Controlled/ Sustained Release Drug Delivery System. *Ind. J. pharm. Sci.* 2005; p 20-30.
2. Vyas, P., Khar, R.K., Controlled drug delivery-concept and advances. 1st ed. Delhi: *Vallabh Prakashan Publishers*; 2002. p. 5-25
3. Florence, L., Juergen, s., Mathias, w., ross, J. M., Roland, B., pH –Sensitive Polymer Blends Used as Coating Materials to Control Drug Release from Spherical Beads: Elucidation of the Underlying Mass Transport Mechanisms. *Pharm. Res.* 2002; 22: 7.
4. Ghebre-Selassie, I., editor. Pharmaceutical Pelletization Technology. *New York: Marcel Dekker Inc.*; 1989; 37: 1-165.
5. Thomas, W.Y.L., Joseph, R.R., Controlled release drug delivery systems. In: Alfonso, R.G., editor. *Remingtons: The science and practice of pharmacy, 20<sup>th</sup> ed. Philadelphia; Lippincott Williams and Wilkins*; 2000;1: 903-930.
6. Schaefer, T., Holm, p., Kristensen, H.G., Melt pelletization in a High shear mixer. Effect of process variables and binder. *Acta. Pharm. Nord.* 1992; 4:133-140.
7. Chien, Y.W., editor. Novel Drug Delivery Systems 2<sup>nd</sup> ed. *New York: Marcel Dekker, Inc*; 1992; 50:43-98.
8. Galmen, M.J., Pellet manufacture for controlled release. *Manuf.chem.* 1985; 56: 55-59.
9. David, M.S., chang, S. K., Dinesh, V.P., James, A.W., Diffuse-interface theory for structure formation and release behavior in controlled drug release systems. *Acta Biomaterialia.* 2007; 851-864.
10. Siepmann, F., Siepmann, J., Walther, M., MacRae, R.J., Bodmeier, R. Polymer blends for controlled release coatings. *J control release.* 2007;4:1-26.

11. Florence, L., Juergen, S., Mathias, W., Ross, J. M., Rooland, B., Polymer blends used for the coating of multiparticulates: comparison of aqueous and organic coating techniques. *Pharm. Res.* 2004; 21:5.
12. The United States Pharmacopeia. The official compendia of standards. 30th ed. *The United States Pharmacopeial Convention: Rockville*; 2008; 2:1367.
13. Claudio, N., Rita, C., Elisabetta, E., Alberto, G., Alessandro, S., Carlo V., et al., Influence of formulation and process parameters on pellet production by powder layering technique. *AAPS Ann. Sc. Tech.* 2000; 1: article 9.
14. Othomer, D.F., “Background, History and Future of Fluid bed Systems” Fluidization. *Newyork: Reinhold Publishing Corporation*; 1956; p 102-115.
15. Swarbrick, J., Boyalan, J.C., “Fluid bed dryer, granulator and coaters. In: Encyclopedia of pharmaceutical technology. *New York: Marcel Dekker Inc.* 1992; 6; 171-173.
16. Bette, L., editor. Physicians Desk Reference. 61th edition. *Montvale: Thomson PDR*; 2007; p 2698-2700.
17. Rowse, R.C., The effect of the molecular weight of ethyl cellulose on the drug release properties of mixed films of ethyl cellulose and hydroxyl propyl methyl cellulose. *Int. J. Pharm. Biopharm.* 1986; 29:37- 41.